Dec 16 (Reuters) – Pfizer on Tuesday forecast 2026 profit below Wall Street estimates as it expects lower sales of its COVID products, sending its shares down 1.6% in premarket trading.
The drugmaker expects adjusted profit of between $2.80 and $3 per share for the coming year, below analysts’ average estimate of $3.05 per share, according to data compiled by LSEG.
It expects revenue for the year in the range of $59.5 billion to $62.5 billion, compared with estimates of $61.59 billion.
That includes the expectation of revenue from COVID-19 products being about $1.5 billion lower than what was expected in 2025.
(Reporting by Puyaan Singh in Bengaluru; Editing by Anil D’Silva)
Brought to you by www.srnnews.com
